Yale study finds rates of PSA testing for prostate cancer increased after revised national guidelines

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Nadeem R. Abu-RustumLouis Burt NaborsMichael J. StylerJames ThompsonErin HeslerNadeem R. Abu-Rustum, Louis Burt Nabors, Michael J. Styler, and James Thompson were recognized by the National Comprehensive Cancer Network as its 2025 awardees who “go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.”

May 30, 2025

Vol.51 No.21

Clinical Trials & Tribulations

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising.

May 23, 2025

Vol.51 No.20

By Peter Nelson

Funding Opportunities

DOD prostate cancer research program FY25 funding opportunities

The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP. Congress provided further guidance for CDMRP program-level funding, including funding for the Prostate Cancer Research Program. The FY25 PCRP intends to support innovative, high-impact prostate cancer research.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

A Johns Hopkins Medicine-led research team has identified a recurrent frameshift mutation, called F722fs, in the MMS22L gene among men of Ashkenazi Jewish ancestry that is associated with a higher risk of prostate cancer and increased sensitivity to a specific anticancer therapy.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Shorter radiation therapy after prostate surgery safe, UCLA study finds

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence.

May 16, 2025

Vol.51 No.19

Clinical Roundup

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

Avenda Health has announced study results showing that its cancer mapping tool, Unfold AI, predicts cancer spread more accurately than MRI.

May 02, 2025

Vol.51 No.17

Yale study finds rates of PSA testing for prostate cancer increased after revised national guidelines

YOU MAY BE INTERESTED IN

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

DOD prostate cancer research program FY25 funding opportunities

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

Shorter radiation therapy after prostate surgery safe, UCLA study finds

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

Renew today!

Subscriber content

Never miss an issue!

Login

Yale study finds rates of PSA testing for prostate cancer increased after revised national guidelines

YOU MAY BE INTERESTED IN

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Biden’s diagnosis is unfortunate but—statistically—not surprisingOf the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

DOD prostate cancer research program FY25 funding opportunities

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

Shorter radiation therapy after prostate surgery safe, UCLA study finds

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

Never miss an issue!

Login

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime